Sponsorship Statement: This continuing education activity is jointly sponsored by 
and 
Support Statement: This activity is supported by an educational grant from 
Target Audience: This program is designed for oncologists and dermatologists.
Learning Objectives:
At the conclusion of this activity, participants should be able to:
- Analyze clinical data evaluating the safety and efficacy of pegylated interferon in the treatment of advanced melanoma.
- Discuss the advantages and limitations of currently available interferon treatment options for patients with metastatic melanoma.
- Review recent data from clinical trials presented at ASCO 2011 regarding melanoma chemotherapy and areas of future research.
Course Chair:
Sanjiv S. Agarwala, MD
Editorial Board Member
HemOnc Today
Professor of Medicine
Temple University School of Medicine
Chief, Oncology & Hematology
St. Luke’s Cancer Center
Bethlehem, Pennsylvania
Faculty:
Peter Mohr, MD
Department of Dermatology
Medical Center Buxtehude
Buxtehude, Germany
Krista M. Rubin, MS, RN, FNP-C
Nurse Practitioner
Massachusetts General Hospital
Boston, Massachusetts
Vernon K. Sondak, MD
Editorial Board Member
HemOnc Today
Department Chair, Cutaneous Oncology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Departments of Surgery & Oncologic Sciences
University of South Florida College of Medicine
Tampa, Florida
Peer Reviewer:
Allan C. Halpern, MD, MSc
Medical Writer:
Marci Landsmann
Accreditation:
This educational activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of HemOnc Today® and Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 10, 2011 to October 10, 2012.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s):
Sanjiv S. Agarwala, MD
Fees for Non-CME Services: Merck and Co, Inc; Novartis
Peter Mohr, MD
Consulting Fees: BMS; Merck and Co, Inc; Roche
Fees for Non-CME Services: BMS; Merck and Co, Inc; Roche
Krista M. Rubin, MS, RN, FNP-C
Consulting Fees: Genentech; Merck and Co, Inc
Vernon K. Sondak, MD
Consultant or Advisory Board Relationship: Abbott; Biovex; BMS/Medarex; Eli Lilly; GlaxoSmithKline; Merck (Schering); Pfizer; Provectus
Speakers’ Bureau: Merck (Schering)
Peer Reviewer reports the following relationship(s):
Allan C. Halpern, MD, MSc
No relevant financial relationships to disclose
Medical Writer reports the following relationship(s):
Marci Landsmann
No relevant financial relationships to disclose
HemOnc Today® and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2011 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of HemOnc Today® and Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of HemOnc Today® and Vindico Medical Education. Neither HemOnc Today®, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.